NewAmsterdam Pharma (NAMS)

• Market cap: $3.56B
• 1 day: -1.47%
• 5 days: -9.48%
• 1 month: -10.31%
• 3 months: -12.36%
• 6 months: 37.88%
• Year to date: -10.77%
• 1 year: 51.15%
• 5 years: 203.48%
• 10 years: 203.48%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77